Study the Average Aerobic Bioburden Levels on Catheters After Use With Egret Catheter and the Predicate Device
NCT ID: NCT01124578
Last Updated: 2010-05-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
200 participants
Study Classification
OBSERVATIONAL
Study Start Date
2008-05-31
Study Completion Date
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE OF EVALUATION: This study will verify \& validate the acceptability of Egret's extended use product as compared to the existing daily change-out product. Based on an extensive in-vitro study, Egret's product confirmed significant kill for both positive and negative gram bacteria. In addition to meeting all of the current product requirements, total aerobic bio-burden on the catheters will be tested at various intervals for up to 10 days of use. The current used product will be used as a control group that is to be changed out daily as per current policy. The control group will be tested for total aerobic bacteria counts on the last day of use.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of a Urethral Catheter Coated With Eluting Silver Salts (SUCCESS)
NCT00482547
Catheterization
TERMINATED
PHASE4
Comparison of Antimicrobial Coated Ureteral Stents With Non-coated Stents
NCT02266368
Quality of Life
COMPLETED
PHASE4
Reuse of Intermittent Urethral Catheters
NCT02129738
Intermittent Urethral Catheterization
COMPLETED
NA
Comparison of an Antibiotic Impregnated PICC Catheter Versus a Regular PICC Catheter in a Tertiary Care Setting
NCT01765738
Peripherally Inserted Central Catheters
WITHDRAWN
PHASE2
Research on the Localization Accuracy of PICC Guided by EDUG in Real World
NCT03230357
Peripherally Inserted Central Catheter
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Protocol
Title: Extended Use In-line Endotracheal Suction Catheter w/BIOSAFE
Protocol Number: RT 2008-001
Study Director: Richard C. Dowdy
Study Director's Address and Method of Contact:
Egret Medical Products Inc. Richard C. Dowdy 2713 Industrial Lane Garland, TX 75041 (214) 291-0238 Phone (817) 991-7459 Cell (214) 291-0243 Fax [email protected]
I. PURPOSE OF EVALUATION: This test will verify \& validate the acceptability of Egret's extended use product as compared to the existing Ballard's daily change-out product. In addition to meeting all of the current product requirements, total aerobic bio-burden on the catheters will be tested at various intervals for up to 10 days of use.
II. BACKGROUND: Prior to this evaluation, a baseline study was conducted at Medical City to determine the existing total aerobic bio-burden after one day of use, using 25 randomly selected Ballard catheters as per the attached protocol. The data from the baseline study were used to establish an appropriate sample size for the Extended Use Protocol. This data gathered under this Extended Use Protocol will be compared to the baseline data to determine the effectiveness of Egret's antimicrobial properties during extended use.
III. POTENTIAL RISK TO PATIENT: Closed endotracheal suction catheters are intended to maintain a hermetical seal. However, such catheters have a propensity to build up bio- film on the tip area and require saline rinsing and cleaning after use. Egret's catheter is compounded with a non-leaching antimicrobial to address this issue. There is the possibility that excessive patient secretions can over saturate any closed suction catheter. Egret has addressed this concern by incorporating a unique squeegee-and-filter design that facilitates tip cleaning and prevents debris from migrating from the cleaning chamber to the sleeve area.
IV. BENEFTS OF THE EGRET MEDICAL DEVICE
1. The catheter contains a non-leaching antimicrobial agent that enables product to be used safely for up to fourteen (10) days.
2. Based on previous in-vitro testing, the Egret product with BIOSAFE has been found to reduce bacteria counts over extended time.
3. Minimizing the frequency of change-out of the closed catheter system will reduce the chance for cross-contamination since the air way will be opened less frequently, e.g., every five days versus daily.
4. Less frequent product change-out reduces the need to manipulate the ET-Tube. The more the ET-Tube is manipulated, the greater the chance upper airway contents trapped above the cuff can enter the pulmonary bed.
5. The catheter reduces bacteria colonization over the span of its use
6. The swivel connector enables accessories to be easily connected and disconnected.
7. An integrated positive lock valve facilitates use and prevents gas from escaping when not in use.
8. A uniquely designed filter is incorporated into the device's manifold that provides a 95% BFE level to prevent cross-contamination to caregiver and patient.
9. Egret's devices are MRI safe - no metal parts are used in assembly.
V. PRODUCT to BE EVALUATED:
Product Code Description Size 454 Egret 14 Fr. T-Piece - Extended use 14 FR/4.6 mm 54 cm (21.75") length
VI. INVESTIGATOR David Barton, BA, RRT, RCP
VII. SPONSOR Egret Medical Products Inc.
VIII. AFFLICATION OF APPLICANT Egret Medical Products Inc.
IX. FUNDING AGIENCIES Egret Medical Products Inc.
X. ANTICIPATED TEST DATES April 2008-May 2008
XI. METHODOLOGY:
1. Egret will provide 100 units of product to support use testing requirements
2. An in-service meeting will be held by Egret facilitators prior to beginning the test to ensure participants are aware of the use test requirements and responsibilities.
3. During the test period, the Egret product will be used instead of the specific normally used for the procedure for up to 10 days if needed.
4. This device is to be used per existing Medical City Policy RCSCC12 with the exception that change- out is not required daily, and that the Egret device can be used up to 10 days or until extubation.
5. Careful instruction is to be given the caregiver on how catheter is to be flushed and rinsed after suctioning. This step is essential to maintain the patency of the catheter as well as to reduce bio- burden that the catheter must combat.
6. Clinical Trial Subject Tracking - As per the attached spreadsheet, product installation and usage is to be tracked by the investigator. Products provided from Egret will be discreetly numbered 1 thru 100 on the bottom of each suction catheter valve.
7. Arrangements have been made with MicroChem Laboratory, Inc. to conduct total aerobic bio-burden using the same the method used for the baseline study.
8. After product has been used, representative samples are to be red bagged and sent by courier to MicroChem to conduct aerobic bacterial testing. Transportation and testing requirements are clearly outlined in an approved test protocol.
9. Egret personnel will be present at Medical City to facilitate and observe the use of the test product for the duration of the test period.
10. At the completion of the test period, healthcare participants will complete a questionnaire concerning the Egret use test product as compared to the existing Ballard product.
11. All test products at the end of the test period will be return to Egret.
12. During the evaluation, if a caregiver perceives defect or failure, the caregiver is to contact the investigator for assessment. Products that are perceived as defective are to be set aside for additional evaluation by Egret.
XII. DATA TO BE COLLECTED: After product has been used, the healthcare participants will complete a written questionnaire concerning the test device as per attached.
XIII. DELIVERY OF PRODUCT: Available test product will be delivered to use-test site as per Medical City instructions.
XIV. RECOVERY OF PRODUCT: The investigator will be responsible for gathering all unused test product and returning it to Egret.
XV. SPECIAL INSTRUCTIONS: Participants will be briefed on the specific features of Egret's extended use product to be tested at their facility.
XVI. TEST FACILITATORS: Egret will provide on-site qualified personnel to assist with resources as required by Medical City.
XVII. APPROVALS
Study Director: Richard C. Dowdy Date: Title: Vice President
The Study Director is responsible for ensuring that no data for use in the Final Report (Outputs) has been generated before protocol approval.
Approvers: Egret Medical Products Inc. Management
Signature(s) indicate that this protocol has been reviewed and understood in its entirety and meets all criteria specified in Section 4.1, Protocol Design and Approval Policy.
Approver: Date: Title:
Approver: Date: Title:
Approver: Date: Title:
Upon approval of the protocol, the original is to be filed at the administrative offices of Egret Medical Products Inc. The study director should retain a copy of the protocol until the report is completed
Endotracheal Suctioning Catheter Use Test Questionnaire
Clinician's Name: Date:
Where Used: Oral Intubation 0 or Trach 0
Product usage questions Not Same as Improved Acceptable Current Use of Change-out label
0 0 0
Connection to suction tubing
0 0 0
Suction Valve - Ease of use
0 0 0
Gauge and feel of sheath material
0 0 0
Valve Locking Safety Feature
0 0 0
Ease of connection to trach or ET tube
0 0 0
Catheter positioning and ease of manipulation
0 0 0
Communication\\visibility of depth markings
0 0 0
Use of saline port
0 0 0
Tip cleaning process and result
0 0 0
Product flexibility to prevent unnecessary ET movement?
0 0 0
Did sheath remain clean and dry? 0 0 0
Affect of heat on product function? 0 0 0
Perceived weight of product 0 0 0
Comfort to patient
0 0 0
Did end cap remain secure?
0 0 0
Ease of disconnect after use?
0 0 0
Did this product meet your expectation? 0 0 0
Additional Comments:
Thank you for your help
Title: Extended Use In-line Endotracheal Suction Catheter w/BIOSAFE
Protocol Number: RT 2008-001
Study Director: Richard C. Dowdy
Study Director's Address and Method of Contact:
Egret Medical Products Inc. Richard C. Dowdy 2713 Industrial Lane Garland, TX 75041 (214) 291-0238 Phone (817) 991-7459 Cell (214) 291-0243 Fax [email protected]
I. PURPOSE OF EVALUATION: This test will verify \& validate the acceptability of Egret's extended use product as compared to the existing Ballard's daily change-out product. In addition to meeting all of the current product requirements, total aerobic bio-burden on the catheters will be tested at various intervals for up to 10 days of use.
II. BACKGROUND: Prior to this evaluation, a baseline study was conducted at Medical City to determine the existing total aerobic bio-burden after one day of use, using 25 randomly selected Ballard catheters as per the attached protocol. The data from the baseline study were used to establish an appropriate sample size for the Extended Use Protocol. This data gathered under this Extended Use Protocol will be compared to the baseline data to determine the effectiveness of Egret's antimicrobial properties during extended use.
III. POTENTIAL RISK TO PATIENT: Closed endotracheal suction catheters are intended to maintain a hermetical seal. However, such catheters have a propensity to build up bio- film on the tip area and require saline rinsing and cleaning after use. Egret's catheter is compounded with a non-leaching antimicrobial to address this issue. There is the possibility that excessive patient secretions can over saturate any closed suction catheter. Egret has addressed this concern by incorporating a unique squeegee-and-filter design that facilitates tip cleaning and prevents debris from migrating from the cleaning chamber to the sleeve area.
IV. BENEFTS OF THE EGRET MEDICAL DEVICE
1. The catheter contains a non-leaching antimicrobial agent that enables product to be used safely for up to fourteen (10) days.
2. Based on previous in-vitro testing, the Egret product with BIOSAFE has been found to reduce bacteria counts over extended time.
3. Minimizing the frequency of change-out of the closed catheter system will reduce the chance for cross-contamination since the air way will be opened less frequently, e.g., every five days versus daily.
4. Less frequent product change-out reduces the need to manipulate the ET-Tube. The more the ET-Tube is manipulated, the greater the chance upper airway contents trapped above the cuff can enter the pulmonary bed.
5. The catheter reduces bacteria colonization over the span of its use
6. The swivel connector enables accessories to be easily connected and disconnected.
7. An integrated positive lock valve facilitates use and prevents gas from escaping when not in use.
8. A uniquely designed filter is incorporated into the device's manifold that provides a 95% BFE level to prevent cross-contamination to caregiver and patient.
9. Egret's devices are MRI safe - no metal parts are used in assembly.
V. PRODUCT to BE EVALUATED:
Product Code Description Size 454 Egret 14 Fr. T-Piece - Extended use 14 FR/4.6 mm 54 cm (21.75") length
VI. INVESTIGATOR David Barton, BA, RRT, RCP
VII. SPONSOR Egret Medical Products Inc.
VIII. AFFLICATION OF APPLICANT Egret Medical Products Inc.
IX. FUNDING AGIENCIES Egret Medical Products Inc.
X. ANTICIPATED TEST DATES April 2008-May 2008
XI. METHODOLOGY:
1. Egret will provide 100 units of product to support use testing requirements
2. An in-service meeting will be held by Egret facilitators prior to beginning the test to ensure participants are aware of the use test requirements and responsibilities.
3. During the test period, the Egret product will be used instead of the specific normally used for the procedure for up to 10 days if needed.
4. This device is to be used per existing Medical City Policy RCSCC12 with the exception that change- out is not required daily, and that the Egret device can be used up to 10 days or until extubation.
5. Careful instruction is to be given the caregiver on how catheter is to be flushed and rinsed after suctioning. This step is essential to maintain the patency of the catheter as well as to reduce bio- burden that the catheter must combat.
6. Clinical Trial Subject Tracking - As per the attached spreadsheet, product installation and usage is to be tracked by the investigator. Products provided from Egret will be discreetly numbered 1 thru 100 on the bottom of each suction catheter valve.
7. Arrangements have been made with MicroChem Laboratory, Inc. to conduct total aerobic bio-burden using the same the method used for the baseline study.
8. After product has been used, representative samples are to be red bagged and sent by courier to MicroChem to conduct aerobic bacterial testing. Transportation and testing requirements are clearly outlined in an approved test protocol.
9. Egret personnel will be present at Medical City to facilitate and observe the use of the test product for the duration of the test period.
10. At the completion of the test period, healthcare participants will complete a questionnaire concerning the Egret use test product as compared to the existing Ballard product.
11. All test products at the end of the test period will be return to Egret.
12. During the evaluation, if a caregiver perceives defect or failure, the caregiver is to contact the investigator for assessment. Products that are perceived as defective are to be set aside for additional evaluation by Egret.
XII. DATA TO BE COLLECTED: After product has been used, the healthcare participants will complete a written questionnaire concerning the test device as per attached.
XIII. DELIVERY OF PRODUCT: Available test product will be delivered to use-test site as per Medical City instructions.
XIV. RECOVERY OF PRODUCT: The investigator will be responsible for gathering all unused test product and returning it to Egret.
XV. SPECIAL INSTRUCTIONS: Participants will be briefed on the specific features of Egret's extended use product to be tested at their facility.
XVI. TEST FACILITATORS: Egret will provide on-site qualified personnel to assist with resources as required by Medical City.
XVII. APPROVALS
Study Director: Richard C. Dowdy Date: Title: Vice President
The Study Director is responsible for ensuring that no data for use in the Final Report (Outputs) has been generated before protocol approval.
Approvers: Egret Medical Products Inc. Management
Signature(s) indicate that this protocol has been reviewed and understood in its entirety and meets all criteria specified in Section 4.1, Protocol Design and Approval Policy.
Approver: Date: Title:
Approver: Date: Title:
Approver: Date: Title:
Upon approval of the protocol, the original is to be filed at the administrative offices of Egret Medical Products Inc. The study director should retain a copy of the protocol until the report is completed
Endotracheal Suctioning Catheter Use Test Questionnaire
Clinician's Name: Date:
Where Used: Oral Intubation 0 or Trach 0
Product usage questions Not Same as Improved Acceptable Current Use of Change-out label
0 0 0
Connection to suction tubing
0 0 0
Suction Valve - Ease of use
0 0 0
Gauge and feel of sheath material
0 0 0
Valve Locking Safety Feature
0 0 0
Ease of connection to trach or ET tube
0 0 0
Catheter positioning and ease of manipulation
0 0 0
Communication\\visibility of depth markings
0 0 0
Use of saline port
0 0 0
Tip cleaning process and result
0 0 0
Product flexibility to prevent unnecessary ET movement?
0 0 0
Did sheath remain clean and dry? 0 0 0
Affect of heat on product function? 0 0 0
Perceived weight of product 0 0 0
Comfort to patient
0 0 0
Did end cap remain secure?
0 0 0
Ease of disconnect after use?
0 0 0
Did this product meet your expectation? 0 0 0
Additional Comments:
Thank you for your help
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Suction Catheter Bioburder Level After Patient Use.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Existing used daily change-out device
No interventions assigned to this group
Egret
Extended Use Catheter w/BIOSAFE
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who agree to consent.
Exclusion Criteria
* Patients who do not agree to consent or with confirmed Ventilator-associated Pneumonia (VAP)are to be excluded from this study.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Egret Medical Products Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medical City Dallas Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Barton, BA, RRT, RCP
Role: PRINCIPAL_INVESTIGATOR
Medical City Hospital, Dallas, TX
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical City Dallas Hospital
Dallas, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
1.Medical City Dallas Hospital, Policies and Procedures, Policy No. RSCC12 - Endotracheal Suctioning 2.MicroChem Labs - A Study to Measure the Total Aerobic Bacteria on Ballard Suction Catheters During 24 Hours Use with Respiratory Care Patients. This study was conducted to establish a baseline bio-burden count of catheter tips after use. 3.Nelson Laboratories - Bacterial Filtration Efficacy, Report No. 413451. This test was preformed to determine the bacterial filtration efficacy of the filter as per ASTM F2101. 4.Micro-Chem Labs - Evaluation of the Antimicrobial Properties of Sterilized and Non-Sterilized Egret Catheters Versus a Non-Treated Control Catheter During Extended Exposure to S. aureus, P. aeruginosa, and K. pneumoniae.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RT 2008-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Components of Chlorhexidine Gluconate Dressing
NCT01112020
COMPLETED
PHASE1
Explorative Clinical Study on the Performance and Acceptance of New Intermittent Catheters in Healthy Volunteers
NCT04231149
COMPLETED
NA
A Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter for Reduction of CAUTI.
NCT01681511
TERMINATED
NA
Exploratory Investigation of Data Obtained From a Sensor Connected to an Intermittent Catheter
NCT04250987
COMPLETED
NA
Use and Acceptability Study of Swallis DSA™ Device for Distanced Swallowing Assessment for Older Adults In Nursing Home CHEZ LES PERSONNES AGEES EN EHPAD
NCT05366374
UNKNOWN
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
NCT01904188
RECRUITING
Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection
NCT02528721
COMPLETED
PHASE3
A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion
NCT04720794
COMPLETED
NA
DUET Versus Standard Interface for Hypercapnic COPD Patients
NCT05829083
RECRUITING
NA
Suturable DuraGen™ PMCF Study
NCT04923867
COMPLETED
DyeVert Pilot Trial
NCT02606734
COMPLETED
NA
Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test
NCT04597047
UNKNOWN
NA
Evaluation of the LumiraDx Point of Care D-Dimer and CRP Tests
NCT04375982
ACTIVE_NOT_RECRUITING
NA
Clinical Trial of New Intermittent Single-use Catheter
NCT05814211
COMPLETED
NA
Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19
NCT04434131
COMPLETED
PHASE2
Study of BD Pre-filled Flush Syringes in China
NCT05763147
COMPLETED
NA
Site Selection for Intracutaneous Saline Delivery
NCT01767324
COMPLETED
NA
New Reusable Mask Design With Superior Filtration and Fit
NCT04826809
COMPLETED
NA
US Post-Market Surveillance Study of the Surfacer System
NCT05050799
RECRUITING
Evaluation of Blood Gas Syringes
NCT01935284
COMPLETED
DyeVert System RCT
NCT02752802
COMPLETED
NA
Clinical Study Evaluating Safety of a New Catheter for Urinary Intermittent Catheter in Healthy Volunteers
NCT01292941
WITHDRAWN
PHASE1
Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections
NCT02796716
COMPLETED
Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study
NCT02446925
TERMINATED
NA
A Trial of effectIveness of a Smart Sensor for Continence Care: the ARCTICC Study
NCT02511314
COMPLETED
NA